Strategies to find, test, and treat people living with hepatitis C in Australia

Event type: 
Event date: 
Wednesday, 27 July 2022 - 12:00pm to 1:30pm
Free - registrations are essential. Please register on the booking link below.


Contact for inquiries: 
Rata Joseph, +61 (2) 9385 0900 or
Booking deadline: 


Australia has committed to eliminating hepatitis C by 2030, with targets to increase diagnoses and treatment, and reduce new infections and liver-related deaths. Hepatitis C therapies with cure rates of over 95% are one of the greatest medical advances in decades, having led to declines in liver-related mortality. Our ability to meet the WHO targets in Australia is threatened by declines in annual hepatitis C RNA testing and treatment.

Ahead of World Hepatitis Day, this special event will include presentations from the Kirby Institute; Hepatitis Australia; Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM); and Burnet Institute on efforts to help find, test, and treat people living with hepatitis C in Australia. The seminar will include a panel discussion on the key requirements that are needed to facilitate hepatitis C elimination as we approach 2030.



Professor Jason Grebely  

Professor Jason Grebely
Professor, Kirby Institute

Jason is Professor and Head of the Hepatitis C and Drug Use Group at the Kirby Institute, UNSW Sydney. Jason is also the President of the International Network on Health and Hepatitis in Substance Users.

Twitter: @jasongrebely



World Hepatitis Day logo on top of sepia toned image of people walking on street  

Mr Stuart Manoj-Margison
Director – Blood Borne Viruses, Sexually Transmissible Infections, and Torres Strait Health Policy Section, Australian Government Department of Health and Aged Care

Stuart leads the section responsible for the coordination of the national response to blood borne viruses and sexually transmissible infections through the five National BBV and STI Strategies, which represent the commitment of Australian governments, researchers and health and community organisations to address the impact of BBVs and STIs on the Australian community.

Ms Carrie Fowlie  

Ms Carrie Fowlie
CEO, Hepatitis Australia

Carrie is the CEO of Hepatitis Australia, the national peak body representing the state and territory hepatitis organisations and the interests of 350,000 Australians impacted by viral hepatitis.

Carrie has two decades of peak body, policy and social justice experience. Her collaborative work has resulted in policy, programs and law reform consistent with the evidence and the priorities of her constituencies.

Twitter: @CarrieFowlie

Ms Emily Adamson  

Ms Emily Adamson
Health Promotion Program Manager, Burnet Institute

Emily is the health promotion program manager and is part of the Eliminate C Australia Partnership team at the Burnet Institute. Emily’s background is health psychology and has over 15 years experience working with a range of community-based organisations in health promotion, chronic disease self management and advocacy. She has developed expertise in translating research to inform program design and implementation with an emphasis in making sure programs, such as communication campaigns, are community led and equitable for people from diverse backgrounds.

Mr Troy Combo  

Mr Troy Combo
Aboriginal Program: EC Australia, Burnet Institute, and University of Queensland

Troy has a joint appointment with the Burnet Institute and is employed and based at University of Queensland and is the Aboriginal Program Manager for Eliminate Hepatitis C Australia Partnership: EC Australia. Troy is a Bundjalung man from the Northern NSW and is a highly regarded leader in Aboriginal health with over twenty years’ experience.

Twitter: @TroyCombo

Ms Shelley Kerr  

Ms Shelley Kerr
Hepatitis C Program Manager, Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)

Shelley is the Hepatitis C Program Manager at the Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine. She is responsible for the management of the Hepatitis C program in Australia and internationally, providing strategic direction for the program to build capacity in the health workforce through collaboration, partnerships, and high-level policy contributions.

Twitter: @ShelleyKerr25

Professor Greg Dore  

Professor Greg Dore
Program Head, Viral Hepatitis Clinical Research Program, Kirby Institute

Greg is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has developed extensive national and international collaborations, and is internationally recognised in the areas of hepatitis C virus (HCV) natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

Twitter: @GregDore2


To learn more about World Hepatitis Day:


Logos of World Hepatitis Day, Kirby Institute, Hepatitis Australia, ASHM and Burnet Institue


Opinions expressed in the Kirby Institute Seminar Series are solely those of the speaker and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.

Header image: kylie De Guia on Unsplash